SOURCE: Trend Exploration, Inc.

January 24, 2011 08:00 ET

TRDX's Wholly Owned Subsidiary, Preferred Distribution, Inc., Announces Its New Pharmaceutical Distribution Division Has Been Approved as a Distributor for Global Pharmaceutical Wholesaler, Hospira

JERICHO, NY--(Marketwire - January 24, 2011) - SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX) is pleased to announce, Preferred Distribution, Inc. ("Preferred"), its medical and dental supplies distribution subsidiary, has recently been approved as a distributor for Hospira, a global pharmaceutical wholesaler ( This distribution relationship now provides Preferred's pharmaceutical division with new products for its distribution pipeline.

The distributorship with Hospira is the first to be completed by Preferred. More dealerships are being pursued as sources of product. Management anticipates the pharmaceutical distribution division will provide a significant source of additional revenue for the company in 2011.

The Company looks forward to announcing more developments as milestones are successfully achieved.

About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)

SciMeDent is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.

About Hospira

Hospira is a global specialty pharmaceutical and medication delivery company, backed by proven leadership and more than 70 years' experience producing high-quality products. Hospira's breadth of offerings help customers address the safety, productivity and cost of patient care. Used by hospitals worldwide, Hospira products are also prevalent in outpatient clinics and other alternate healthcare sites.

Cautionary Statement Regarding Forward-Looking Statements

A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company's business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.

Contact Information